Cara hauls in $70M on first leg of global deal, setting up PhIII kidney disease drug for commercial roll out
Cara Pharmaceuticals, a small biotech in Connecticut, is licensing out its late-stage kidney disease drug in a deal that gives a Swiss pharmaceutical company commercialization rights across the globe.
Cara inked the deal with a joint venture formed by two public companies: Vifor Pharma and Fresenius Medical Care, the latter of which is the largest kidney dialysis provider in the US. The joint venture goes by Vifor Fresenius Medical Care Renal Pharma, or VFMCRP for short (but let’s be honest, it could be shorter).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
